NextEra Energy, Lennar And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. stock futures were mixed this morning, with the Nasdaq futures gaining around 0.2% on Tuesday. Shares of…
UroGen Pharma Announced Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it has commenced an underwritten
Hasbro, Tutor Perini, Arm Holdings And Other Big Stocks Moving Higher On Friday
U.S. stocks were mostly lower, with the Dow Jones index falling around 300 points on Friday. Shares of…
Hasbro To Rally Around 38%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst…
UroGen Pharma Announces Date For ENVISION Data, Long-Term Jelmyto Durability Data, To Be Discussed During Company Sponsored Virtual Event On June 13, 2024
12-month duration of response data from ENVISION study of UGN-102 to be discussed during company sponsored virtual event on June 13, 2024ENVISION data expected to support completion of UGN-102 NDA in Q3 2024Post-hoc
Reported Sunday, JELMYTO Demonstrates Remarkable 86% Recurrence-Free Survival Rate At 24 Months For All Studied Patient And Disease Characteristics
There Were No Differences in RFS Regarding Usage for Chemoablation or Post-Endoscopic Ablation, Tumor Size, Multifocality, or Tumor Location
RFS Was 100% in Patients who Received Maintenance therapy
UroGen Announces FDA Acceptance Of IND Application For UGN-103, A Next Generation Mitomycin-Based Formulation For Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
UroGen plans to initiate a Phase 3 study to explore the safety and efficacy of UGN-103 in 2024Anticipated advantages include a new 80 mg mitomycin dosage strength that may considerably shorten the manufacturing process,
UroGen Pharma Files Patent Infringement Action Against Teva Pharmaceuticals Alleging Infringement Of US Patent Numbers 9,040,074 And 9,950,069
UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced that it has filed a lawsuit in the U.S.
UroGen Initiates Submission Of A Rolling NDA To The FDA For UGN-102
UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced the submission of the Chemistry, Manufacturing,
Two Months After Hamas Attacks, Gaza Conflict Intensifies As Ceasefire Efforts Falter
Two months after Hamas attacks, US President Biden, UNSC & King of Jordan call for ceasefire. Israeli stocks rise, US envoy to UN against ceasefire. Investigations into civilian casualties & use of phosphorus munitions. UNSC to convene tomorrow.